Reply to T. Lang et al

Journal of Clinical Oncology

Volumn 28, Issue 25, 2010, Pages

  Kiyotani, Kazuma ^a   Mushiroda, Taisei ^a   Nakamura, Yusuke ^b   Zembutsu, Hitoshi ^b  

^a RIKEN   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 2; TAMOXIFEN;

ALLELE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; ELECTROPHORETIC MOBILITY; GENE SEQUENCE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79951923834     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.8349     Document Type: Letter

References (5)

1. Lang T, Schroth W, Brauch H, et al: ABCC2 and clinical outcome of tamoxifen therapy. J Clin Oncol 28:e448, 2010
2. Kiyotani K, Mushiroda T, Imamura CK, et al: Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28:1287-1293, 2010
3. Sai K, Saito Y, Itoda M, et al: Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. Drug Metab Pharmacokinet 23:139-147, 2008
4. Choi JH, Ahn BM, Yi J, et al: MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics 17:403-415, 2007 (Pubitemid 46763385)
5. Sai K, Saito Y, Maekawa K, et al: Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol 66:95-105, 2010